rs4680
|
COMT;MIR4761
|
Malignant neoplasm of prostate
|
|
0.090 |
GeneticVariation |
BEFREE |
The AA genotype and the A allele of rs4680 (COMT) appeared to be inversely associated with the risk of prostate cancer in adjusted models for both Afro-Caribbean and native African men.
|
27074016 |
2016 |
rs4680
|
COMT;MIR4761
|
Malignant neoplasm of prostate
|
|
0.090 |
GeneticVariation |
BEFREE |
We suggest that bladder cancer but not prostate cancer and kidney cancer could be significantly associated with the Val158Met polymorphism.
|
27055785 |
2016 |
rs4680
|
COMT;MIR4761
|
Malignant neoplasm of prostate
|
|
0.090 |
GeneticVariation |
BEFREE |
Collectively, the results of the present study suggest that significant associations o</span>f COMT Val158Met polymorphisms with prostate cancer were observed (for additive model: OR = 1.068, 95 % CI = 1.002-1.138, P (heterogeneity) = 0.363, P = 0.043; for dominant model: OR = 1.266, 95 % CI = 1.057-1.517, P (heterogeneity) = 0.000, P = 0.011; for recessive model: OR = 1.050, 95 % CI = 0.961-1.146, P (heterogeneity) = 0.558, P = 0.279; and Val allele versus Met allele OR = 0.932, 95 % CI = 0.894-0.971, P (heterogeneity) = 0.272, P = 0.001).
|
23096092 |
2013 |
rs4680
|
COMT;MIR4761
|
Malignant neoplasm of prostate
|
|
0.090 |
GeneticVariation |
BEFREE |
There is no association between the COMT Val158Met polymorphism and PCa.
|
23116175 |
2013 |
rs4680
|
COMT;MIR4761
|
Malignant neoplasm of prostate
|
|
0.090 |
GeneticVariation |
BEFREE |
This meta-analysis suggests that COMT Val158Met polymorphism might not be a risk factor for PCa risk.
|
23257985 |
2013 |
rs4680
|
COMT;MIR4761
|
Malignant neoplasm of prostate
|
|
0.090 |
GeneticVariation |
BEFREE |
Our results suggested that the Val158Met polymorphism of COMT was not associated with the risk of sporadic or latent prostate cancer in Japanese men.
|
17760745 |
2007 |
rs4680
|
COMT;MIR4761
|
Malignant neoplasm of prostate
|
|
0.090 |
GeneticVariation |
BEFREE |
To investigate potential non-receptor-mediated estrogen effects, we evaluated the association between COMT Val158Met and hOGG1 Ser326Cys polymorphisms and prostate cancer in a family-based case-control study (439 prostate cancer cases, 479 brother controls).
|
16569655 |
2006 |
rs4680
|
COMT;MIR4761
|
Malignant neoplasm of prostate
|
|
0.090 |
GeneticVariation |
BEFREE |
A total of 11 htSNPs (including COMT Val(158)Met) were selected based on the resequencing and dense genotyping approach of the Breast and Prostate Cancer Cohort Consortium. htSNPs were genotyped in a population-based, case-control study in Poland (1,995 cases and 2,296 controls).
|
17018638 |
2006 |
rs4680
|
COMT;MIR4761
|
Malignant neoplasm of prostate
|
|
0.090 |
GeneticVariation |
BEFREE |
The Val158Met polymorphism of COMT is associated with the PSA-progression-free rate of EMP-treated patients in prostate cancer.
|
16126332 |
2005 |